Remove tag small-molecules
article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Rather than investing more in R&D, most pharma companies feel its more cost-effective to buy small biotech companies developing unique molecules that can find a market niche.

Pharma 210
article thumbnail

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. Across the world, to varying degrees, the regulations were written in an era of small molecules and biologics. AZ: How can regulators ensure that they nurture future innovations in the field?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Advanced therapies and the high-profile pricing dilemma

pharmaphorum

Previously, the discovery of small molecule treatments had been the priority, with their development and manufacturing process being an established formula. This is how small molecule treatments typically work and, as a result, this was how the entire industry formed over the last century to create a profitable enterprise.

Medicine 125
article thumbnail

Putting complex medicines under the microscope

European Pharmaceutical Review

A new wave of medicines has emerged in recent years to supplement the well-established small and large molecule platforms that have historically dominated the market. It is vital to ensure adequate exposure in the target tissue, tailoring product performance to patient needs and the properties of the molecule and target.